Omnicell, Inc
Omnicell, Inc. designs and sells medication management technology for healthcare providers, including automated dispensing systems, robotics, smart devices, software workflows, and related services. The company serves hospitals, health systems, pharmacies, and specialty pharmacy customers primarily in the United States, with additional activity in Canada and other international markets.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueNonrecurring automation hardware, software licenses, and related product revenue.
Recurring product consumables used with dispensing and medication management systems.
Recurring support, maintenance, and implementation-related services.
Subscription software and specialized pharmacy services including EnlivenHealth and 340B offerings.
Products
Reported · share of revenue- Connected Devices Software Licenses and Other47.7 %
- Technical Services21.9 %
- Saa S and Expert Services21.9 %
- Consumables8.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Omnicell sells to hospitals, health systems, outpatient pharmacies, provider groups, and federally qualified health centers. Its solutions are used by pharmacists and nurses to automate medication handling, improve inventory control, and support compliance across inpatient and outpatient care settings.
Hospitals and integrated delivery networks buy dispensing automation, software, and services to standardize medication workflows and improve control.
Outpatient and retail pharmacy customers use software, devices, and services to manage prescriptions, adherence, and operational efficiency.
Provider groups, FQHCs, and health systems use specialty pharmacy access, payer contracting, and LDD support.
Healthcare providers buy 340B and inventory optimization tools to manage reimbursement, compliance, and supply chain complexity.
Strategy
Omnicell’s strategy centers on the Autonomous Pharmacy vision: combining automation, software, services, and analytics to reduce manual medication handling and improve pharmacy operations. The company is also expanding recurring revenue through SaaS, expert services, and specialty pharmacy offerings while continuing to develop its platform through acquisitions and product innovation.
A unified platform increases customer dependence and supports cross-selling across hardware, software, and services.
Subscriptions and services can improve revenue visibility and deepen customer relationships.
These offerings extend the platform into higher-need pharmacy workflows and reimbursement complexity.
Technology and product additions can expand the installed base and address adjacent workflows.
Geography
Q1/2026Omnicell generates the large majority of its revenue in the United States, and its sales force is organized around U.S. and Canadian customer segments. The company also serves healthcare facilities in other countries, but its operating footprint and revenue exposure remain concentrated in North America.
Share of the revenue the company reports by geography.
Risks
Omnicell faces demand, competitive, regulatory, and technology risks tied to healthcare automation and pharmacy services. Its business is also exposed to supply-chain constraints, cybersecurity, customer credit and lease financing risk, and the challenge of maintaining access to specialty drugs and pharmacy networks.
- Customer demand and adoption riskImpact: HighLikelihood: Medium
Hospitals and pharmacies may delay or reduce purchases of automation and services in weak conditions.
Exposure: Medication management solutions and related services
- Competitive pressureImpact: HighLikelihood: Medium
The company competes against larger healthcare technology and pharmacy automation vendors.
Exposure - Healthcare regulatory and compliance riskImpact: HighLikelihood: Medium
Products and services operate in a heavily regulated environment with privacy, fraud, and anti-kickback exposure.
Exposure - Cybersecurity and data security riskImpact: HighLikelihood: Medium
Software and connected devices create exposure to breaches, outages, and service disruption.
Exposure - Specialty pharmacy access riskImpact: High
Loss of access to limited distribution drugs or pharmacy networks could reduce customer value.
Exposure: Specialty Pharmacy Services
- Supply chain and component availability riskImpact: MediumLikelihood: Medium
Hardware products depend on raw materials, components, and third-party vendors.
Exposure: Connected devices and automation systems
Accounting
Judgemental itemsThe company sells nonrecurring products and recurring services, so timing of recognition affects comparability.
Impact: Hardware, software licenses, consumables, SaaS, and expert services
Automation hardware requires component inventory and valuation judgments.
Impact: Gross margin and write-down risk
Prior acquisitions created significant goodwill and intangibles that must be tested for impairment.
Impact: Potential noncash impairment charges
Tax estimates can vary with jurisdictional mix and uncertain tax positions.
Impact: Quarterly earnings volatility
Similar listed companies
Publicly listed companies with a comparable business focus.
OMNIQ Corp.
OMQS · Services-Computer Integrated Systems Design
OmniAb, Inc.
OABIW · Services-Commercial Physical & Biological Research
Insulet Corporation
PODD · Surgical & Medical Instruments & Apparatus
Insulet Corporation develops, manufactures, and sells the Omnipod platform, a tubeless continuous insulin delivery system for people with insulin-dependent diabetes.
Omnicom Group Inc
OMC · Services-Advertising Agencies
Omnicom Group is a U.S.-based strategic holding company for a portfolio of advertising, media, public relations, precision marketing, commerce, and specialty communications agencies.
Stimcell Energetics Inc.
STME · Surgical & Medical Instruments & Apparatus
INVO Fertility, Inc.
IVF · Surgical & Medical Instruments & Apparatus
Last updated: 24/09/2026